TRT and Liver Health: Understanding Risks and Monitoring MASLD

Last Updated: APRIL 2024

Low testosterone is independently associated with an increased prevalence and severity of non-alcoholic fatty liver disease (NAFLD) in men, a condition now commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). A large cross-sectional study published in the Journal of Clinical Endocrinology & Metabolism (2015) involving over 2,000 men found a significant inverse correlation between total testosterone levels and the risk of NAFLD, indicating that lower testosterone is linked to a higher likelihood of liver fat accumulation. Understanding the nuances of testosterone replacement therapy (TRT) and its impact on liver health is critical for any man considering or currently on treatment.

Understanding Liver Enzymes on TRT

Monitoring liver health on TRT typically involves periodic blood tests for liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These enzymes are released into the bloodstream when liver cells are damaged. Elevated levels can signal liver stress or injury. Other markers like gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) may also be monitored, providing a broader picture of liver and bile duct health. While significant elevations are concerning, it is important to understand that standard TRT protocols with modern delivery methods generally pose a low risk to liver function.

Testosterone Delivery Methods and Hepatic Impact

The method by which testosterone is delivered plays the most significant role in its potential impact on liver health.

Oral C17-alpha Alkylated Androgens: High Hepatic Risk

Historically, some oral testosterone formulations were chemically altered at the 17-alpha position (C17-alpha alkylated) to make them resistant to breakdown in the liver, allowing for oral absorption. Examples include methyltestosterone and fluoxymesterone. These compounds, while orally bioavailable, are known for their high hepatotoxicity, leading to cholestatic jaundice, peliosis hepatis, and even liver tumors with prolonged use. For this reason, C17-alpha alkylated androgens are generally avoided for TRT and are rarely prescribed for this purpose in modern medicine. They are not part of standard, safe TRT protocols.

Injectable Testosterone Esters: Low Hepatic Risk

The most common TRT delivery method involves intramuscular injections of testosterone esters such as:

• Testosterone Cypionate: Typically dosed at 100–200mg per week, administered every 3.5 to 7 days.
• Testosterone Enanthate: Similar dosing to cypionate, 100–200mg per week, every 3.5 to 7 days.
• Testosterone Undecanoate (Nebido/Aveed): A longer-acting ester, administered less frequently (e.g., 1000mg every 10–14 weeks after initial loading doses).

These injectable forms bypass the liver’s first-pass metabolism, directly entering the bloodstream. The testosterone then undergoes normal metabolic processes in the body, including eventual breakdown in the liver, but without the initial high concentration stress seen with C17-alpha alkylated oral forms. Clinical studies consistently show that injectable testosterone, when administered at physiological replacement doses (total testosterone levels targeting 500–1000 ng/dL), has a very low risk of causing clinically significant liver enzyme elevations or liver damage.

For instance, a systematic review published in Clinical Endocrinology (2016) examining the safety of testosterone therapy in men concluded that “oral 17α-alkylated androgens are hepatotoxic, but other testosterone formulations (injectables, transdermals, testosterone undecanoate oral) have not been shown to be associated with significant hepatotoxicity.” This reinforces that standard injectable TRT is a safe option regarding liver health.

Transdermal Testosterone: Low Hepatic Risk

Transdermal gels and patches also bypass first-pass liver metabolism. Testosterone is absorbed through the skin directly into the systemic circulation.

• Testosterone Gels: Typically applied daily, delivering 50–100mg of testosterone per day (equivalent to ~5–10g of 1% gel), which translates to a weekly absorption comparable to injectable doses.
• Testosterone Patches: Applied daily, delivering 2.5–7.5mg of testosterone per day.

Similar to injectables, transdermal testosterone is considered to have a low risk of liver toxicity. While minor, transient elevations in liver enzymes have been reported in some studies, these are generally not clinically significant and often normalize without intervention.

Oral Testosterone Undecanoate (Jatenzo, Kyzatrex): Moderate Hepatic Risk, but Different

A newer oral formulation, testosterone undecanoate (e.g., Jatenzo, Kyzatrex in the US; often sold as Andriol or Restandol in other regions), is distinct from the hepatotoxic C17-alpha alkylated forms. This formulation is designed to be absorbed via the lymphatic system, largely bypassing the initial intense first-pass metabolism by the liver. While safer than C17-alpha alkylated versions, it still involves passage through the liver eventually. For this reason, regular monitoring of liver enzymes is recommended with oral testosterone undecanoate, typically targeting dosages of 200-400mg daily, split into two doses.

Other TRT Adjuncts: Minimal Direct Hepatic Impact

• Human Chorionic Gonadotropin (HCG): Often used at dosages of 500–1000 IU per week (split into 2-3 injections) alongside testosterone to maintain testicular function and fertility. HCG is a peptide hormone and has no known direct hepatotoxic effects at standard TRT adjunct doses.
• Anastrozole: An aromatase inhibitor, typically used at very low doses (e.g., 0.125–0.5mg once or twice per week) to manage elevated estradiol (E2) levels on TRT (optimal E2 range for men on TRT is generally 20–40 pg/mL). Anastrozole is metabolized in the liver but has not been shown to cause significant hepatotoxicity at these low TRT-specific doses. Liver enzyme monitoring is standard but concerns about direct liver damage from anastrozole are minimal.
• Enclomiphene: A selective estrogen receptor modulator (SERM), sometimes used as an alternative to testosterone for men aiming to preserve fertility, typically dosed at 12.5–25mg daily. Enclomiphene works on the hypothalamus and pituitary, stimulating endogenous testosterone production. While all medications carry some risk, enclomiphene has not been associated with significant hepatotoxicity in clinical trials, though baseline and periodic liver enzyme monitoring is still prudent.

The Anti-